According to a recent LinkedIn post from Andelyn Biosciences, the company is collaborating with ENCell, a biotherapeutics CDMO in the Asia-Pacific region, to create what is described as a strategic manufacturing bridge between the U.S. and APAC. The post indicates that Andelyn intends to combine its viral vector development and GMP manufacturing capabilities with ENCell’s regional clinical and manufacturing presence.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The LinkedIn post suggests this partnership is aimed at accelerating global delivery of gene therapies and expanding access for patients in multiple geographies. For investors, this could signal an effort by Andelyn to increase its international footprint, diversify its customer base, and position itself more competitively in the growing cell and gene therapy CDMO market.
The collaboration may enhance Andelyn’s ability to support more global programs by leveraging ENCell’s existing infrastructure in Asia-Pacific. If effectively executed, this expanded manufacturing and clinical reach could translate into higher demand for Andelyn’s services, potentially improving revenue visibility and strengthening its role in cross-border gene therapy development.
More broadly, the post underscores ongoing consolidation and partnership trends within the CDMO and gene therapy ecosystem. By pursuing a U.S.–APAC bridge model, Andelyn appears to be aligning with biopharma sponsors seeking integrated global supply chains, which may be a differentiating factor as competition in advanced therapies manufacturing continues to intensify.